-
Uncategorized3 days ago
Fueled by M&A and partnerships, biotech is poised for continued growth: EY
Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum into 2026, as the volume and value of licensing and M&A deals continues to...
-
Uncategorized3 days agoSTAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
LONDON — GSK said Tuesday it would buy the cancer-focused biotech Nuvalent in a deal worth $10.6 billion, as the British firm continues its expansion in...
-
Uncategorized3 days agoAlcohol study discarded by Trump officials is published in scientific journal
WASHINGTON — A report on alcohol’s health effects, commissioned by the federal government but unreleased under President Trump, came out Tuesday — in a scientific journal....
-
Uncategorized3 days ago
Defective HIV RNA Linked to Persistent Viremia During Long-Term ART
Antiretroviral therapy (ART) has enabled most people living with HIV to live long and healthy lives. However, a small portion of people experience detectable traces of...
-
Uncategorized3 days ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
Nature Biotechnology, Published online: 09 June 2026; doi:10.1038/s41587-026-03172-7 Hybrid solid–liquid optics improve light-sheet imaging of intact biological samples.
-
Uncategorized3 days agoHealth workers at the epicenter of Congo’s Ebola outbreak labor with little pay or rest
MONGBWALU, Congo — Dr. Richard Lokudu, the medical director of Mongbwalu General Referral Hospital, has received barely any compensation for his work on the front line...
-
Uncategorized3 days agoCity banks nearly $100M for next-gen RNAi drugs
Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon...
-
Uncategorized3 days ago
Regeneron-backed City builds RNAi pipeline with $99.5M series B
Regeneron-backed City builds RNAi pipeline with $99.5M series B
-
Uncategorized3 days ago
City Therapeutics builds RNAi pipeline with $99.5M series B
City Therapeutics, one of BioSpace’s NextGen companies for 2026, was started by RNA royalty John Maraganore, former CEO of Alnylam.
-
Uncategorized3 days ago
Chikungunya Vaccine Development in Africa Accelerated by ACT-CHIK
Institut Pasteur is launching ACT-CHIK (Accelerating Clinical Trials for CHIKungunya Vaccine in Africa), a four-year research project funded by the Global Health EDCTP3 Joint Undertaking under...
An obesity drug deep-dive, and peptides move mainstream
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
